Charles River Laboratories International (CRL) Tax Expense: History & Chart

Charles River Laboratories International, Inc.(CRL)

Medical - Diagnostics & Research · Wilmington, MA

$278.35+0.00 (+0.00%)

Delayed quote: Sep 9, 2026, 4:00 PM EDT

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA

19,000 employees

www.criver.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Birgit Girshick

View full financials

Income Tax Expense

The latest quarterly tax expense is $53.93 Million. Income tax expense is the amount a company pays in federal, state, and foreign income taxes based on its taxable income for the period.

EBT|Net Income|Free Cash Flow|Revenue|Income Statement

Tax Expense

CRL Tax Expense

$53.93M

Reported quarterly tax expense; no daily interpolation. Quarter ended Jun 2026 (2026-06-27): $53.93M.

+246.48% over 10Y

Current Tax Expense

$53.93M

$53.93 Million

QoQ Growth

N/A

Historical Data

Quarters of data available

Quarterly Tax Expense History

Period	Tax Expense	QoQ Growth	YoY Growth
Quarter ended Jun 2026Period end 2026-06-27	$53.93M	N/A	N/A
Quarter ended Mar 2026Period end 2026-03-28	−$15.14M	N/A	N/A
Quarter ended Dec 2025Period end 2025-12-27	−$17.81M	N/A	N/A
Quarter ended Sep 2025Period end 2025-09-27	$31.64M	N/A	N/A
Quarter ended Jun 2025Period end 2025-06-28	$18.73M	N/A	N/A
Quarter ended Mar 2025Period end 2025-03-29	$10.10M	N/A	N/A
Quarter ended Dec 2024Period end 2024-12-31	−$3.04M	N/A	N/A
Quarter ended Sep 2024Period end 2024-09-28	$20.95M	N/A	N/A
Quarter ended Jun 2024Period end 2024-06-29	$25.39M	N/A	N/A
Quarter ended Mar 2024Period end 2024-03-30	$24.53M	N/A	N/A
Quarter ended Dec 2023Period end 2023-12-31	$19.75M	N/A	N/A
Quarter ended Sep 2023Period end 2023-09-30	$24.85M	N/A	N/A
Quarter ended Jul 2023Period end 2023-07-01	$29.22M	N/A	N/A
Quarter ended Apr 2023Period end 2023-04-01	$27.09M	N/A	N/A
Quarter ended Dec 2022Period end 2022-12-31	$55.81M	N/A	N/A
Quarter ended Sep 2022Period end 2022-09-24	$25.50M	N/A	N/A
Quarter ended Jun 2022Period end 2022-06-25	$33.45M	N/A	N/A
Quarter ended Mar 2022Period end 2022-03-26	$15.62M	N/A	N/A
Quarter ended Dec 2021Period end 2021-12-31	$23.82M	N/A	N/A
Quarter ended Sep 2021Period end 2021-09-25	$18.11M	N/A	N/A
Quarter ended Jun 2021Period end 2021-06-26	$37.58M	N/A	N/A
Quarter ended Mar 2021Period end 2021-03-27	$2.37M	N/A	N/A
Quarter ended Dec 2020Period end 2020-12-31	$28.24M	N/A	N/A
Quarter ended Sep 2020Period end 2020-09-26	$32.66M	N/A	N/A
Quarter ended Jun 2020Period end 2020-06-27	$16.28M	N/A	N/A
Quarter ended Mar 2020Period end 2020-03-28	$4.62M	N/A	N/A
Quarter ended Dec 2019Period end 2019-12-31	$25.05M	N/A	N/A
Quarter ended Sep 2019Period end 2019-09-28	−$317.00K	N/A	N/A
Quarter ended Jun 2019Period end 2019-06-29	$14.69M	N/A	N/A
Quarter ended Mar 2019Period end 2019-03-30	$10.60M	N/A	N/A
Quarter ended Dec 2018Period end 2018-12-31	$14.85M	N/A	N/A
Quarter ended Sep 2018Period end 2018-09-29	$12.40M	N/A	N/A
Quarter ended Jun 2018Period end 2018-06-30	$17.44M	N/A	N/A
Quarter ended Mar 2018Period end 2018-03-31	$9.77M	N/A	N/A
Quarter ended Dec 2017Period end 2017-12-31	$98.10M	N/A	N/A
Quarter ended Sep 2017Period end 2017-09-30	$19.95M	N/A	N/A
Quarter ended Jul 2017Period end 2017-07-01	$22.24M	N/A	N/A
Quarter ended Apr 2017Period end 2017-04-01	$31.08M	N/A	N/A
Quarter ended Dec 2016Period end 2016-12-31	$18.45M	N/A	N/A
Quarter ended Sep 2016Period end 2016-09-24	$15.56M	N/A	N/A
Quarter ended Jun 2016Period end 2016-06-25	$18.84M	N/A	N/A
Quarter ended Mar 2016Period end 2016-03-26	$13.97M	N/A	N/A
Quarter ended Dec 2015Period end 2015-12-31	$16.73M	N/A	N/A
Quarter ended Sep 2015Period end 2015-09-26	$15.26M	N/A	N/A
Quarter ended Jun 2015Period end 2015-06-27	$11.08M	N/A	N/A
Quarter ended Mar 2015Period end 2015-03-28	$331.00K	N/A	N/A
Quarter ended Dec 2014Period end 2014-12-31	$11.65M	N/A	N/A
Quarter ended Sep 2014Period end 2014-09-27	$11.58M	N/A	N/A
Quarter ended Jun 2014Period end 2014-06-28	$14.08M	N/A	N/A
Quarter ended Mar 2014Period end 2014-03-29	$10.36M	N/A	N/A
Quarter ended Dec 2013Period end 2013-12-31	$3.58M	N/A	N/A
Quarter ended Sep 2013Period end 2013-09-28	$11.39M	N/A	N/A
Quarter ended Jun 2013Period end 2013-06-29	$8.22M	N/A	N/A
Quarter ended Mar 2013Period end 2013-03-30	$9.72M	N/A	N/A
Quarter ended Dec 2012Period end 2012-12-31	$3.49M	N/A	N/A
Quarter ended Sep 2012Period end 2012-09-29	$6.01M	N/A	N/A
Quarter ended Jun 2012Period end 2012-06-30	$9.45M	N/A	N/A
Quarter ended Mar 2012Period end 2012-03-31	$8.68M	N/A	N/A
Quarter ended Dec 2011Period end 2011-12-31	$5.58M	N/A	N/A
Quarter ended Sep 2011Period end 2011-09-24	$5.63M	N/A	N/A
Quarter ended Jun 2011Period end 2011-06-25	$8.65M	N/A	N/A
Quarter ended Mar 2011Period end 2011-03-26	−$2.71M	N/A	N/A
Quarter ended Dec 2010Period end 2010-12-31	−$29.29M	N/A	N/A
Quarter ended Sep 2010Period end 2010-09-25	$16.30M	N/A	N/A
Quarter ended Jun 2010Period end 2010-06-26	$6.53M	N/A	N/A
Quarter ended Mar 2010Period end 2010-03-27	$6.48M	N/A	N/A
Quarter ended Dec 2009Period end 2009-12-31	$9.04M	N/A	N/A
Quarter ended Sep 2009Period end 2009-09-26	$6.90M	N/A	N/A
Quarter ended Jun 2009Period end 2009-06-27	$13.63M	N/A	N/A
Quarter ended Mar 2009Period end 2009-03-28	$10.16M	N/A	N/A
Quarter ended Dec 2008Period end 2008-12-31	$6.28M	N/A	N/A
Quarter ended Sep 2008Period end 2008-09-27	$20.82M	N/A	N/A
Quarter ended Jun 2008Period end 2008-06-28	$17.92M	N/A	N/A
Quarter ended Mar 2008Period end 2008-03-29	$16.93M	N/A	N/A
Quarter ended Dec 2007Period end 2007-12-31	$12.18M	N/A	N/A
Quarter ended Sep 2007Period end 2007-09-29	$16.81M	N/A	N/A
Quarter ended Jun 2007Period end 2007-06-30	$15.10M	N/A	N/A
Quarter ended Mar 2007Period end 2007-03-31	$15.31M	N/A	N/A
Quarter ended Dec 2006Period end 2006-12-31	$12.57M	N/A	N/A
Quarter ended Sep 2006Period end 2006-09-30	$15.49M	N/A	N/A
Quarter ended Jul 2006Period end 2006-07-01	$9.87M	N/A	N/A
Quarter ended Apr 2006Period end 2006-04-01	$12.04M	N/A	N/A
Quarter ended Dec 2005Period end 2005-12-31	−$19.33M	N/A	N/A
Quarter ended Sep 2005Period end 2005-09-24	$12.59M	N/A	N/A
Quarter ended Jun 2005Period end 2005-06-25	$12.46M	N/A	N/A
Quarter ended Mar 2005Period end 2005-03-26	$10.86M	N/A	N/A
Quarter ended Dec 2004Period end 2004-12-31	$9.17M	N/A	N/A
Quarter ended Sep 2004Period end 2004-09-25	$15.78M	N/A	N/A
Quarter ended Jun 2004Period end 2004-06-26	$16.06M	N/A	N/A
Quarter ended Mar 2004Period end 2004-03-27	$20.15M	N/A	N/A
Quarter ended Dec 2003Period end 2003-12-31	$13.13M	N/A	N/A
Quarter ended Sep 2003Period end 2003-09-27	$12.54M	N/A	N/A
Quarter ended Jun 2003Period end 2003-06-28	$12.98M	N/A	N/A
Quarter ended Mar 2003Period end 2003-03-29	$12.41M	N/A	N/A
Quarter ended Dec 2002Period end 2002-12-31	$11.39M	N/A	N/A
Quarter ended Sep 2002Period end 2002-09-28	$11.04M	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.

Data as of June 27, 2026